Show us the PR or other data specifying the "horrible results" as a single agent. They aren't even done with the PI single agent trial, so there is no final data. They have offered some preliminary data that shows surprising results as a single agent. Why surprising? Because the drug is not expected to cure cancer on its own - it only attacks the hypoxic regions of the tumor, leaving the rest untreated, so it will really only be in the combo trials that TH-302 proves its real worth. In the pre-clinical work, TH-302 did worse as a single agent when compared against the currently approved standard chemo agents. But in combination, TH-302 generated never before seen cure rates in several cancer models. As the CEO stated in the recent presentation, they were not expecting to see much efficacy in the PI single agent trials, so the fact that they have some major tumor response rates is significant.